Compare Organon & Co. Common Stock (OGN) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Tripadvisor Inc Common Stock — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Tripadvisor Inc Common Stock trades at $8.93 (market cap $1.02B). The key difference: Organon & Co. Common Stock is far larger — about 3.5× Tripadvisor Inc Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Tripadvisor Inc Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Tripadvisor Inc Common Stock for 58 Days on average.
| OGN | TRIP | |
|---|---|---|
Market Cap | $3.62B | $1.02B |
Volume | 2,892,999 | 1,973,736 |
Sector | Health | Consumer Cyclical |
52-Week High | $13.81 | $16.72 |
52-Week Low | $5.70 | $8.04 |
Typical Hold Time | 0 Days | 58 Days |
Enterprise Value | $11.04B | $1.08B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
TripAdvisor (TRIP) trades at $8.93, up 2.41% today but near its 52-week low of $8.27. The stock shows neutral technical signals with bearish moving averages. Fundamentally, revenue grew to $1.89B in 2025 with a net income margin of 2.11%, though recent quarters show earnings misses. The P/E ratio of 218.5 reflects high valuation relative to earnings, while P/S of 0.57 suggests reasonable sales valuation. Analyst sentiment is mixed with 62.5% hold ratings.
The outlook remains cautious due to competitive pressures from AI travel tools and uneven demand. Upside exists if Viator performance improves and TheFork sale completes, but risks include persistent earnings volatility and market share erosion. The consensus price target of $13.58 offers 52% potential upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
